EP2031010B1 - Verfahren zur herstellung von neuem siliciumdioxid-nanoteilchen und verwendung des siliciumdioxid-nanoteilchens - Google Patents

Verfahren zur herstellung von neuem siliciumdioxid-nanoteilchen und verwendung des siliciumdioxid-nanoteilchens Download PDF

Info

Publication number
EP2031010B1
EP2031010B1 EP07744912.2A EP07744912A EP2031010B1 EP 2031010 B1 EP2031010 B1 EP 2031010B1 EP 07744912 A EP07744912 A EP 07744912A EP 2031010 B1 EP2031010 B1 EP 2031010B1
Authority
EP
European Patent Office
Prior art keywords
silica
mps
particles
particle
ammonia water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Not-in-force
Application number
EP07744912.2A
Other languages
English (en)
French (fr)
Other versions
EP2031010A4 (de
EP2031010A1 (de
Inventor
Michihiro Nakamura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Tokushima NUC
Original Assignee
University of Tokushima NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Tokushima NUC filed Critical University of Tokushima NUC
Publication of EP2031010A1 publication Critical patent/EP2031010A1/de
Publication of EP2031010A4 publication Critical patent/EP2031010A4/de
Application granted granted Critical
Publication of EP2031010B1 publication Critical patent/EP2031010B1/de
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/588—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with semiconductor nanocrystal label, e.g. quantum dots
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
    • C08G77/02—Polysilicates
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
    • C08G77/04—Polysiloxanes
    • C08G77/06—Preparatory processes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
    • C08G77/04—Polysiloxanes
    • C08G77/22—Polysiloxanes containing silicon bound to organic groups containing atoms other than carbon, hydrogen and oxygen
    • C08G77/28—Polysiloxanes containing silicon bound to organic groups containing atoms other than carbon, hydrogen and oxygen sulfur-containing groups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/101666—Particle count or volume standard or control [e.g., platelet count standards, etc.]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/109163—Inorganic standards or controls

Definitions

  • the present invention relates to a method for producing a novel nano silica particle and application thereof. More specifically, the present invention relates to an MPS particle (MPS: 3-mercapto-propyltrimethoxysilane, or 3-mercapto-propyltriethoxysilane; hereafter to be abbreviated as "MPS") that is a silica particle or a silica sphere that has remarkably excellent features as compared with conventional silica particles. Further, in the present specification, preparation of silica particles having remarkably excellent features by various silica supply sources in addition to MPS will be described.
  • MPS 3-mercapto-propyltrimethoxysilane, or 3-mercapto-propyltriethoxysilane
  • TEOS tetraethylorthosilane
  • silica particles are TEOS particles.
  • surface layer of such TEOS particles has lower chemical reactivity (binding ability to foreign protein or nucleic acid)
  • activation by introduction of acceptor group based on a silica compound other than the TEOS has been attempted (Patent Document 1).
  • silica compound tetraethoxysilane (OH group), mercapto-propylethoxysilane (SH group), amino-propylethoxysilane (NH 2 group) (one in parenthesis is "acceptor group” to be introduced) and the like are known.
  • conventional activated silica particles have double structure composed of inner shell comprising TEOS and outer shell comprising acceptor group, and costs of time, labor, and the like required for producing thereof have been expensive.
  • preparation of silica particle has been generally made using tetraethoxysilane (TEOS) and the number of reports dealing with preparation of particles from other silica compounds such as MPS is small.
  • MPS particles obtained according to the method disclosed by Patent Document 2 is advantageous in that cavity formation characteristics is high and surface area is expanded due to cavities formed.
  • the technology as described in Patent Document 1 has been already developed, in which functional materials are bound to silica compound to be mixed with reaction solution for particle formation, and incorporated to particle lattice to allow functional materials to be contained in particle at high concentration, the amount of functional materials which may be contained in one particle becomes higher with lower cavity formation characteristics, and this is useful by just that much, and therefore, the method described in Patent Document 2 resulting in higher cavity formation characteristics can not be said to be useful for a case where the object is to take functional materials.
  • the cavity formation characteristics when cavity formation characteristics is high in the particle, internal structure is reduced and site where functional materials can be arranged is reduced, and this is disadvantageous for internal functionalization (fluorescence intensity per one particle is low). Further, when cavity formation characteristics is high, although surface area increases in some case, there are problems of control of void content and control of functional material arrangement (quantitative arrangement is difficult), and therefore, this can not be said to be useful unless effective embodiment is exemplified. Meanwhile, when cavity formation characteristics is low, internal structure increases, site where functional materials can be arranged increases, and this is advantageous for internal functionalization (fluorescence intensity per one particle is high).
  • the surface area is simple surface area only, this surface area correlates with particle diameter, quantitative arrangement of functional materials becomes possible, and this is useful for quantitative analysis. Therefore, it can be said that one of superiorities which "non-pored" particle has to be utilized as size marker or fluorescent marker is high ability of internal functionalization.
  • An object of the present invention is to resolve problems with prior art as described above.
  • Specific example of problems include drawbacks of conventional type silica particles as described above including TEOS particles, such as high production costs, and low chemical reactivity (binding ability to foreign protein or nucleic acid).
  • the object of the present invention is to provide silica particles in which functionality and quality are excellent and yet mass production is possible with low costs as compared with conventional silica particles.
  • the present invention has been completed by originality and ingenuity, and diligence efforts extended thus far based on a discovery of an extraordinary phenomenon that "MPS particles are produced quickly if ammonia water is added to MPS, which is conventionally used as ligand agent, mixed, and then heated".
  • silica particle relating to the present invention, surface layer, surface and production method thereof have the following nonconventional features or characteristics with regard to effects:
  • the number of types of reagents required for production is less (surfactant, hydrochloric acid or the like are not used),mass production is possible by production process with one reaction stage or one reaction step; the number of container, tube, flask, tank or the like required for production is, depending on production scale, one.
  • fluorescent dye-containing silica particle of the present invention completes a reaction in one stage, different from conventional dye-containing particle.
  • silica compound aminopropyl trimethoxysilane (APS) having amino group (a) and NHS bound dye obtained by binding of NHS reactive with amino acid and dye (b) are reacted to produce APS-dye conjugate (c).
  • APS-dye conjugate (c) is added to particle synthesis reaction using TEOS (d) to incorporate the dye into silica particles via APS.
  • TEOS TEOS
  • dye-containing particles are formed by one-stage reaction.
  • the reaction can be completed in one stage by simultaneously performing a formation of MPS-dye conjugate, obtained by binding of maleimide group reactive with thiol group and dye and a particle formation reaction by MPS. That is, the reaction is showed schematically as follows:
  • silica particles Added value of silica particles is enhanced through remarkable reduction in production costs of conventional silica particles, improvement of functions and quality, diversification and expansion of applications or the like.
  • An efficient and potent means is provided for bioassay in medical care, environmental conservation or the like, qualitative tests, quantitative tests, diagnosis or the like.
  • Nano material “nano scale substance” or “nano substance” denotes ultrafine substance at nano scale, and normally exhibits distinguishing characters different from substances which show bulky feature in reaction against external stimulus (heat, light, voltage or the like).
  • Examples of form of the nano scale substance include zero-dimensional structure (sphere), one-dimensional structure (needle, line), two-dimensional structure (membrane, plate), and three-dimensional structure (bulk). Examples of zero-dimensional structure include cluster, ultrafine particle, quantum dot, and dendrimer.
  • one-dimensional structure include nano tube, nano wire, and quantum wire.
  • Examples of two-dimensional structure include nano sheet, nano belt, nano membrane, hetero junction, and quantum well.
  • Examples of three-dimensional structure include nano ceramics, nano metal, and nanostructure filter.
  • Example of fine particle form of nano material includes “nano particle”.
  • Nano particle is a particle with diameter of several tens nano meters. This particle is turned to cluster as a result of aggregation, reaction, growth of atoms and molecules, and stabilization and arrangement, the cluster then makes development.
  • sica particle silica particle
  • NP nano silica particle
  • sica compound As used herein, “silica compound”, “silane compound”, “silane derivative”, and “silicon compound” are used interchangeably, denote compounds composed primarily of silicon (Si) atom, intend to play a role of supply source for providing silicon to the relevant particle upon producing nano particle, are compounds provided in the form of, for example, SiR 1 R 2 R 3 R 4 (R 1 , R 2 , R 3 , and R 4 are respectively arbitrary organic group), are more preferably mercapto-propyl-trimethoxysilane (MPS), mercapto-propyl-triethoxysilane (MPES), mercapto-propyl-methyldimethoxysilane (MPDMS), trimethoxy[2-(7-oxabicyclo[4.1.0]-hepto-3-yl)ethyl]silane(EpoPS), thiocyanatopropyltriethoxysilane (TCPS), and acryloxypropyltrimethoxys
  • bottom-up method is a method in which atoms or molecules are interacted by physical or chemical method for scale-up purpose. Controls are possible in the order of atoms and molecules.
  • bottom-up method include laser radiation method (membrane growth method), self-assembly method, chemical vapor deposition method, sol-gel method, coagulation-sedimentation method, and combinatorial chemistry method.
  • Top-down method is a method in which miniaturization is performed by destroying or processing bulky substances, and examples thereof include lithography method and etching method.
  • sol-gel method, gas phase method, spray method or the like are used as nano particle synthesis.
  • sol-gel method is a method in which liquid in sol state is dried to convert it to gel state and solid is synthesized ( Stober, W.: Fink, A.; Bohn, E.J. Colloid Interface Sci., 1968, 26, 62 ⁇ 69 ).
  • sol-gel method (Stober method) is utilized.
  • nano particles are produced at room temperature in the particle production step.
  • "High-temperature condition" in the production method of a silica particle and a group of silica particles of the present invention means reaction condition within a temperature range of 70 to 100°C, preferably 80 to 100°C, more preferably 90 to 100°C.
  • High ammonia condition in the production method of a silica particle and a group of silica particles of the present invention means that concentration of ammonia water prepared is not less than 20% at final concentration and is preferably 20% to 30%, 25% to 30%, 26% to 28%, more preferably 27%.
  • medium ammonia concentration means concentration of ammonia water prepared at final concentration of not less than 10% and less than 20%.
  • Low ammonia concentration means concentration of ammonia water prepared at final concentration of not less than 2% and less than 5%.
  • “high ammonia condition” when ammonia is used in sol-gel method, several percent of ammonia concentration is used in the conventional method, and "high ammonia condition" used in the present invention is not used therein.
  • lattice and “silica network” in nano particle of the present invention are used interchangeably, and the lattice of particles represents internal structure as the primary particle and intends a stereoscopic structure in mesh form via chemical bond represented by Si-O-, Si-C-, or the like.
  • the present invention relates to "non-pored” silica particle or "without pore” silica particle.
  • features of "non-pored” or “without pore” are such that, for example, there is no “macro pore” and there is no pore of 20 ⁇ m or more.
  • non-pored silica particle of the present invention has, for example, specific surface area of 4.816 (m 2 /g) in particles having average particle diameter of about 900 nm, and pore volume is 0.0159 (m 3 /g).
  • Pore is a term showing porous structure, and the pore is largely classified into micro pore, meso pore, and macro pore.
  • Micro pore denotes pores having a diameter of not more than 2 nano meters (nm).
  • Moso pore denotes pores having a diameter in a range of 2 to 50 nano meters (nm).
  • macro pore denotes pores having a diameter of 50 nano meters (nm).
  • Substantially spherical as used for particles denotes particles in spherical shape without presenting irregular structure due to that there is no pore.
  • Gas adsorption method is one of the most common means for obtaining pore distribution, specific surface area or the like. The method is performed by a specific surface area pore distribution measuring device from Beckman-Coulter. With this method, pore distribution and specific surface area can be measured based on BET theory.
  • particle diameter is an index showing magnitude of particles of measurement target and can be expressed by the diameter of the particle.
  • particle diameter can be measured and determined by various technologies. For example, particle diameter can be determined using a transmission electron microscope.
  • size distribution or “grain size distribution” are used interchangeably, and “size distribution” shows distribution pattern of "particle diameter” in the group of particles of measurement target.
  • size distribution can be measured by various technologies, size distribution of particles can be assessed using flow cytometry or the like.
  • particle diameter distribution width is an index showing degree of dispersibility of "particle diameter” in “size distribution” and shows a width where particle diameter of target particles exists.
  • one of features of particle diameter distribution width is that particle diameter distribution width in the target group of particles is of narrow area distribution within ⁇ 25% of the average particle diameter.
  • Flow cytometry is a means for optically analyzing individual particle while fine particles (for example, single cell of floating cell in sheath liquid) are dispersed in a fluid and this fluid is flown in a slender stream.
  • Light beam with constant wavelength normally laser light
  • FSC forward scatter
  • SSC side scatter
  • intensity of the forward scatter light is proportional to surface area of measurement target particle and hence is used as an index showing magnitude of fine particles thereof
  • side scatter since caused by refraction and scatter of a measurement target, can be used as an index for complication of internal structure.
  • side scatter light is used for a case where positive correlation is found between particle diameter of particle family used and side scatter light.
  • size marker denotes a substance that plays a role of giving an index for quantitative determination of size for measurement target system.
  • acceptor group denotes a functional group introduced onto silica particle or silica sphere. Relationship between silica compound used for silica particle formation and acceptor group to be introduced is, for example, in the following correspondence relationship: [Table 1A] Silica compound (4) Acceptor group formed on silica sphere surface Tetraethoxysilane OH group ⁇ -mercaptopropyltriethoxysilane SH group Aminopropyltriethoxysilane NH 2 group 3-thiocyanatopropyltriethoxysilane SCN group 3-glycidyloxypropylethoxysilane Epoxy group 3-isocyanatopropyltriethoxysilane CNO group
  • functional material denotes a substance bearing physical, chemical or biological actions and its form is arbitrary as long as it has a site interacting with a target to act.
  • functional material include medical agent, fluorescent substance, protein, peptide, nucleotide, nucleotide analog, oligonucleotide, oligonucleotide analog, and sugar chain, but not limited thereto.
  • fluorescent substance denotes a substance that emits fluorescence when being excited by external stimulus such as electromagnetic wave (e.g., ultraviolet ray, X-ray, electron beam).
  • electromagnetic wave e.g., ultraviolet ray, X-ray, electron beam.
  • fluorescent substance include rhodamine red, fluorescein, hexane acid-6-(tetramethyl rhodamine-5-carboxamide), hexane acid-5-(tetramethyl rhodamine-5-carboxamide), Alexa Fluor 647, DY 635, DY 485, DY 495, DY 505, and tris dichlororuthenium (II) hexahydrate, but not limited thereto.
  • the fluorescent substance is present in silica particles in, for example, the aspects shown in (1) to (4) below, but not limited thereto. That is; (1) they are contained independently inside; (2) reaction product of one in which fluorescent substance and a compound selected from N-hydroxy succinimide (NHS) and isothiocyanate (ITC), and 3-(aminopropyl)triethoxysilane is contained inside or exists on the surface layer in a form bound to the silica network; (3) reaction product of one bound to maleimide and MPS is contained inside or exists on the surface layer in a form bound to the silica network; or (4) one in which fluorescent substance and maleimide are bound exists on the surface layer due to reaction with silica particle containing silica compound having thiol.
  • NHS N-hydroxy succinimide
  • ITC isothiocyanate
  • 3-(aminopropyl)triethoxysilane is contained inside or exists on the surface layer in a form bound to the silica network
  • surface layer functionalization denotes that functional materials are disposed on the surface layer of silica particle of the present invention and are stabilized. Further, properties of target particles capable of performing the surface layer functionalization is expressed as internal functionalization capability. As used herein, “to stabilize” is to provide a physically and chemically stabilized state required for that the functional material realizes a desired function with repeatability in silica particles under use environments thereof.
  • internal functionalization denotes that functional material is contained in the silica particle of the present invention and is stabilized. Further, properties of the target particle capable of performing the internal functionalization are expressed as internal functionalization capability.
  • proteins proteins
  • polypeptide oligopeptide
  • peptide polymer of amino acid with arbitrary length and altered body thereof.
  • the polymer may be straight chain, branched or cyclic.
  • the amino acid may be natural, nonnatural, or altered amino acid. This term encompasses those which could be assembled to a complex of a plurality of polypeptide chains. This term also encompasses natural or artificially altered amino acid polymer. Examples of such alterations include disulfide bonding, glycosylation, lipidation, acetylation, phosphorylation, or other arbitrary manipulation or alteration (e.g., conjugation to labeling molecule).
  • protein is preferably a protein compatible with a host in which the composition should be used, but any protein may be used as long as it is processed to be compatible with the relevant host. Whether or not a certain protein has compatibility with the host, and whether or not it can be processed so as to be compatible with the host can be determined by observing if it is colonized in the host by implanting the protein to the host and suppressing, if necessary, side reaction such as immunological rejection reaction.
  • examples of protein having compatibility as described above can include a protein derived from the host, but not limited thereto.
  • nucleotide denotes a nucleotide where sugar part thereof is ester phosphate, which encompasses DNA and RNA, and which may be natural one or nonnatural one.
  • nucleotide means a compound in which base and sugar are N-glycoside-bond.
  • Nucleotide derivative or “nucleotide analogue” denotes one that is different from naturally-occurring nucleotide, but has the same functions as original nucleotide. Such nucleotide derivative and nucleotide analogue are well known in the art.
  • nucleotide derivative and nucleotide analogue examples include phosphorothioate, phosphor amidate, methyl phosphonate, chiralmethyl phosphonate, 2-O-methyl ribonucleotide, peptide nucleic acid (PNA), but not limited thereto.
  • DNA encompasses cDNA, genome DNA, synthetic DNA.
  • support denotes a material capable of fixing a target substance.
  • materials for the support include arbitrary solid material having characteristics binding to a substance such as biological molecule usable in the present invention in either covalent binding or noncovalent binding or can be derivatized so as to have such characteristics.
  • Silica particle of the present invention can be utilized as the support.
  • silica particles of the present invention have useful characteristics and develop remarkable effects due to these characteristics as compared with conventional silica particles, while silica particles having features of the present invention can also be prepared from at least one silica compound selected from a group consisting of mercapto-propyl-triethoxysilane (MPES), mercapto-propyl-methyldimethoxysilane (MPDMS), trimethoxy[2-(7-oxabicyclo[4.1.0]-hepto-3-yl)ethyl]silane(EpoPS), thiocyanatopropyltriethoxysilane (TCPS), and acryloxypropyltrimethoxysilane (AcPS).
  • MPES mercapto-propyl-triethoxysilane
  • MPDMS mercapto-propyl-methyldimethoxysilane
  • Silica particles were prepared with a similar manner as in Example 4 except for variation of amount of used MPS for ammonia water (constant amount) and alteration of I/N volume ratio [volume of isopropanol solution (I) : volume (N) of 28% by weight ammonia water]. Results are shown in Table 2. Positive correlation was found between amount of used MPS (concentration) for ammonia water (constant amount) and particle diameter. Meanwhile, no definite correlation was found between I/N ratio and particle diameter.
  • silica compound containing rhodamine (labeling molecule) was prepared in advance, and (b) silica sphere containing rhodamine (labeling molecule) was prepared using the silica compound obtained.
  • Rhodamine Red TM C2 maleimide (about 5 mg) was dissolved into 50 ⁇ l of DMSO solution, (3-mercaptopropyl)-trimethoxysilane) having thiol group was added and mixed to be equimolar to the Rhodamine Red TM C2 maleimide, stirred using a tube mixer under light shielding for 2 hours and reacted to prepare silica compound containing rhodamine (labeling molecule), and presented for preparation of (b) silica sphere.
  • reaction solution containing silica compound containing rhodamine (labeling molecule) obtained in above (a) was added 7.5 ⁇ l of MPS and about 675 ⁇ l of 27% by weight ammonia water, mixed, and reacted at 100°C for about 11 hours. Subsequently, the reaction completed solution was loaded to high-speed centrifugal machine (10,000 x g; 5 minutes), and pellets were collected therefrom. The pellets were washed with 70% by volume ethanol and distilled water alternately. Washing was performed repeatedly by centrifugation for total 6 times. Pellets collected (silica particle) were stirred and dispersed by the ultrasonic crushing machine, sampled, and observed by fluorescence microscope, and it was confirmed that particles emitted fluorescence of rhodamine.
  • This confirmation means that the present invention has very useful characteristics as compared with conventional art. Namely, one obtained by binding of N-hydroxy succinimide ester reactive with amino acid and fluorescent dye and amino group of APS were reacted to form APS-fluorescent dye conjugate, it was then mixed when preparing silica particle with the resultant and TEOS or the like, and with silica particle containing fluorescent dye, amino group (positive charge) of unreacted APS was neutralized with Si-O- (negative charge) of silica, and particle agglomeration occurred due to reduction in surface charge of the particles, while in the present example, MPS-fluorescent dye conjugate was formed by reaction of one obtained by binding of maleimide reactive with thiol group and fluorescent dye, and thiol group of MPS, it was then mixed when preparing silica particle using the resultant and MPS, and MPS silica particle containing fluorescent dye could be prepared without causing agglomeration.
  • Rhodamine Red TM C2 maleimide (about 5 mg) was dissolved into 73.5 ⁇ l of DMSO solution, 3 ⁇ l of MPS particle solution prepared in above (1) was added, stirred and reacted with the tube mixer under light shielding for 2 hours. Subsequently, the reaction completed solution was loaded to high-speed centrifugal machine (10,000 x g; 5 minutes), and pellets were collected therefrom. The pellets were washed repeatedly with 70% ethanol and distilled water alternately. Washing was performed repeatedly by centrifugation for total 6 times.
  • ⁇ Purpose> To perform bioassay on glass plate with nano silica particle mediation method. ⁇ Method> (a) 0.2 ⁇ l of MPS silica particle was spotted on the glass substrate and dried; (b) 2 ⁇ l of goat GST antibody (from Amersham Corp.) of various concentrations (10 ng/ml to 30 ⁇ g/ml) was dropped on spots of silica particle, reacted in a moist chamber at room temperature for 5 minutes, and washed; (c) using PBS solution containing 1% BSA, blocking reaction was performed in the moist chamber at room temperature for 10 minutes and washed; (d) using 7.5 ⁇ g/ml of Cy3 labeled anti-goat antibody IgG (from Jakson Corp.), reaction was performed in the moist chamber at room temperature for 1 hour, and washed; (e) fluorescence intensity of each spot was measured by fluorescence image analyzer (TAKARA FM BIO II).
  • ⁇ Purpose> To perform bioassay on glass plate with nano silica particle mediation method. ⁇ Method> (a) 0.2 ⁇ l of MPS silica particle was spotted on the glass substrate and dried; (b) 2 ⁇ l of goat anti-GST antibody (from Amersham Corp.) of various concentrations (10 ng/ml to 30 ⁇ g/ml) was dropped on spots of silica particle, reacted in the moist chamber at room temperature for 5 minutes, and washed; (c) blocking reaction was performed with PBS solution containing 2% skim milk in the moist chamber at room temperature for 5 minutes, and then washed; (d) reaction was performed with rhodamine labeled purified enzyme GST in the moist chamber at room temperature for 1 hour, and then washed; (e) fluorescence intensity of each spot was measured by fluorescence image analyzer (TAKARA FM BIO II).
  • reaction solution containing silica compound (fluorescein-APS) containing 5 mM fluorescein (labeling molecule) were added 1 ⁇ l of MPS and about 675 ⁇ l of 27% by weight ammonia water, and reacted at 100°C for about 10 hours. Subsequently, the reaction completed solution was loaded to high-speed centrifugal machine (10,000 x g; 5 minutes), and pellets were collected therefrom. The pellets were washed with 70% ethanol and distilled water alternately. Washing was performed repeatedly by centrifugation for total 6 times. Pellets collected (silica particle) were stirred and dispersed by the ultrasonic crushing machine, and particles (average particle diameter 96 nm) were obtained.
  • silica spheres were measured and assessed by flow cytometry FACS Calibur HG.
  • fluorescence due to MPS particles was confirmed in the form of a clear group and peak (purple (lower left) and light green (lower right): upper left of FIG. 2 (b) is referenced for the both).
  • Fluoresbrite supplied by Polyscience was used as the size marker.
  • fluorescence of fluorescent nano silica particles as extremely small as average particle diameter of about 100 nm was successfully detected.
  • the peak was located between M4 and M3 of Fluoresbrite, i.e., between fluorescent peaks of 1.0 ⁇ m and 2.0 ⁇ m particles, thereby indicating that the present particle emits fluorescence intensity equivalent to Fluoresbrite of about 10-fold size. It is considered the result thus obtained a result obtained by incorporating dyes by non-pored particles in high density.
  • the following table shows results of preparation of particles of the present invention (MPS, MPES, MPDMS, AcPS, EpoS, and TcPS) attempted under the conditions described in Patent Document 2. Particles formed (o), no particle formed ( ⁇ ), and there are incomplete particles ( ⁇ ) are shown. Time in the table shows time elapsed (15 minutes, 30 minutes, 8 hours) after initiation of base treatment which was carried out after acid treatment (2 days).
  • time for acid treatment is 1 to 3 days, and for base treatment, ethanol is added at 5 minutes after or immediately after. It is interpreted that ethanol added was used to stop reaction by base treatment. That is, it is interpreted that according to the method of Patent Document 2, micelle formation and modest particle solidification were performed by acid treatment, and complete particle solidification was performed by base treatment. It is therefore considered that time for base treatment is short, the reason for performing ethanol treatment is to make particle solidification reaction nonuniform, and area where solidification is insufficient becomes pores.
  • silica sphere containing rhodamine (labeling molecule) was prepared from silica compound containing rhodamine (labeling molecule). Specifically, 7 ⁇ l of reaction solution containing silica compound containing rhodamine (labeling molecule) obtained as described above, 7.5 ⁇ l of MPS, and about 675 ⁇ l of 27% by weight ammonia water were added, and reacted at 100°C for about 11 hours. The solution obtained (reaction completed solution) was subjected to centrifugal sedimentation by the high-speed centrifugal machine (10,000 ⁇ g; 5 minutes), pellets obtained were washed with 70% ethanol and distilled water repeatedly for several times. Particles subjected to centrifugal sedimentation were stirred by the ultrasonic crushing machine, these silica spheres were observed by the fluorescent microscope, and it was confirmed that particles emitted fluorescence of rhodamine.
  • Rhodamine Red TM * (about 5 mg) was dissolved in 50 ⁇ l of DMSO solution, then 3-aminopropyltriethoxysilane (APS) containing amino group was added to be equimolar to above Rhodamine Red TM * C2 maleimide, stirred and reacted with the tube mixer under light shielding for about 2 hours to prepare silica compound containing rhodamine (labeling molecule).
  • APS 3-aminopropyltriethoxysilane
  • silica sphere containing rhodamine was prepared from rhodamine (labeling molecule) containing silica compound.
  • reaction solution containing silica compound containing rhodamine (labeling molecule) obtained as described above, 7.5 ⁇ l of MPS, and about 675 ⁇ l of 27% by weight ammonia water were added, and reacted at 100°C for about 11 hours.
  • the solution obtained (reaction completed solution) was subjected to centrifugal sedimentation by the high-speed centrifugal machine (10,000 ⁇ g; 5 minutes), pellets obtained were washed with 70% ethanol and distilled water repeatedly for several times.
  • silica compound containing 5-carboxytetramethylrhodamine (labeling molecule) was prepared in advance, and (b) silica spheres containing TAMRA (labeling molecule) were prepared using the silica compound thus obtained.
  • TAMRA 5-carboxytetramethylrhodamine
  • succinimidyl ester compound As succinimidyl ester compound, after 5-carboxytetramethylrhodamine succinimidyl ester (5-TAMRA-SE) (about 1.7 mg) was dissolved in 85 ⁇ l of DMSO solution, as silica compound having amino group, 3-(aminopropyl)triethoxysilane (APS) was added to be equimolar to above 5-TAMRA-SE and mixed, stirred and reacted with the tube mixer under light shielding for 2 hours to prepare silica compound containing TAMRA (labeling molecule), and presented to preparation of the following (b) preparation of silica spheres.
  • 5-TAMRA-SE 5-carboxytetramethylrhodamine succinimidyl ester
  • APS 3-(aminopropyl)triethoxysilane
  • silica compound containing Alexa Fluor 647 was prepared in advance, and (b) silica sphere containing Alexa Fluor 647 (labeling molecule) was prepared using the silica compound thus obtained.
  • Alexa Fluor 647 C2-maleimide (about 1 mg) was dissolved in 50 ⁇ l of DMSO solution, and then (3-mercaptopropyl)-trimethoxysilane having thiol group was added to be equimolar to the Alexa Fluor 647 C2-maleimide, mixed, and stirred and reacted with the tube mixer under light shielding for 2 hours to prepare silica compound containing Alexa Fluor 647 (labeling molecule), and presented to the following (b) preparation of silica spheres.
  • silica compound containing DY 635 (labeling molecule) was prepared in advance, and (b) silica sphere containing DY 635 (labeling molecule) was prepared using the silica compound thus obtained.
  • succinimidyl ester compound DY 635 N-hydroxysuccinimide ester (about 1 mg) was dissolved in 25 ⁇ l of DMSO solution, and then 3-(aminopropyl)triethoxysilane (APS) was added as silica compound having amino group to be equimolar to above DY 635, mixed, and stirred and reacted with the tube mixer under light shielding for 2 hours to prepare silica compound containing DY 635 (labeling molecule), and presented to the following (b) preparation of silica spheres.
  • APS aminopropyl
  • silica compound containing DY 495 (labeling molecule) was prepared in advance, and (b) silica sphere containing DY 495 (labeling molecule) was prepared using the silica compound thus obtained.
  • succinimidyl ester compound DY 495-X/5- N-hydroxy succinimide ester (about 5 mg) was dissolved in 25 ⁇ l of DMSO solution, and then 3-(aminopropyl)triethoxysilane (APS) was added as silica compound having amino group to be equimolar to above DY 495, mixed, and stirred and reacted with the tube mixer under light shielding for 2 hours to prepare silica compound containing DY 495 (labeling molecule), and presented to the following (b) preparation of silica spheres.
  • APS aminopropyl
  • silica compound having amino group to be equimolar to above DY 495 mixed, and stirred and reacted with the tube mixer under light shielding for 2 hours to prepare silica compound containing DY 495 (labeling molecule), and presented to the following (b) preparation of silica spheres.
  • silica compound containing DY 505 (labeling molecule) was prepared in advance, and (b) silica sphere containing DY 505 (labeling molecule) was prepared using the silica compound thus obtained.
  • succinimidyl ester compound DY 505X/5-N-hydroxysuccinimide ester (about 5 mg) was dissolved in 25 ⁇ l of DMSO solution, and then 3-(aminopropyl)triethoxysilane (APS) was added as silica compound having amino group to be equimolar to above DY 505, mixed, and stirred and reacted with the tube mixer under light shielding for 2 hours to prepare silica compound containing DY 505 (labeling molecule), and presented to the following (b) preparation of silica spheres.
  • silica spheres containing trisdichlororuthenium (II) hexahydrate were prepared by a method for doping the dye to particles.
  • FIG. 22 shows cases with dye and FIG. 23 shows cases without dye. It can be confirmed in FIG. 22 that peaks move dominantly in FL2 and FL3 by fluorescent emission as compared with FIG. 23. It can be confirmed that dyes are taken into particles favorably, thereby emitting fluorescence.
  • Forming rate of MPS NP was compared with forming rate of TEOS NP under the same conditions with transmission electron microscope (TEM).
  • TEOS NP could be observed clearly at 9 hours after initiation of reaction ( FIG. 9a to FIG. 9c ).
  • TEOS NP did not change significantly after one day elapsed and before 2nd day. Therefore, it is judged that TEOS NP is formed thoroughly within the first 9 hours of the reaction time. Contrary to this, formation of MPS particles proceeds in different fashion. Interface portion of the products is indistinct after 9 hours elapsed, some are fused each other, and others are separated ( FIG. 9d ). Subsequently, the products were washed with 70% ethyl alcohol/water and then loaded to the centrifugal machine (10,000 ⁇ g; 5 minutes), and nano particles were not collected. Two days later, definite MPS NP was observed ( FIG. 9e and FIG. 9f ). These results suggest that formation of MPS NP takes place slower than TEOS NP under the same conditions.
  • MPS particle growth process for MPS is different from particle growth process for TEOS.
  • formation of TEOS NP by Stober method, formation of TEOS NP is started by hydrolysis of silica precursor by ammonium hydroxide, then self-polymerization, formation of silica matrix, and sedimentation of TEOS NP follow.
  • Detailed mechanism of formation of MPS NP has not been identified yet.
  • MPS reaction mixture became clouded in several hours, MPS particles were not recovered after washing step.
  • Another process is assumed that first, MPS micelle is formed, and then hydrolysis and polymerization of MPS due to ammonium hydroxide occur in the micelle, thereby forming nano particles.
  • MPS nano particles exhibit a broad size distribution depending on concentration of MPS in the reaction mixture. That is, size distribution of TEOS NP is different from that of MPS NP.
  • size of TEOS NP is in a range of 250 nm to 570 nm ( FIG. 9c ), while size of MPS NP is in a range of 350 nm to 1200 nm ( FIG. 9f ).
  • MPS NP having narrow size distribution is needed for a certain application, and the present inventors have studied methods for preparing such MPS NP. It is considered that MPS is capable of producing dipodal alkoxysilane by formation of disulfide binding between thiol residues of MPS, and alkoxysilane obtained can produce POM nano particles.
  • the present inventors synthesized MPS NP and TEOS NP containing fluorescence dye as follows.
  • the present inventors characterized these particles and compared with quantum dot.
  • Weight per one particle was calculated using 4 ⁇ ⁇ ((Diameter/2) 3 /3) (nm 3 ) ⁇ 2.3 (specific gravity). It was assumed to divide concentration by weight per particle, and the number of fluorescent nano silica particles was calculated. b. Intensity was divided by the number of particles. c. Intensity was divided by the number of particles and further divided by cubic volume of one particle.
  • Fluorescence intensity of quantum dot Q-dot 605 was assessed under the following two conditions.
  • the first conditions are same as the conditions for assessment of fluorescence intensity of fluorescent nano silica particles containing rhodamine red.
  • excitation wavelength and luminescence wavelength are 570 nm and 590 nm, respectively.
  • the second conditions are optimum conditions for Q-dot 605.
  • excitation wavelength and luminescence wavelength are 350 nm and 605 nm, respectively.
  • fluorescence intensity of MPS NP containing rhodamine is higher than fluorescence intensity of quantum dot. This is considered to be attributable to when the size of nano silica particles is greater and the amount of dyes incorporated is large.
  • specific fluorescence intensity was calculated by dividing total fluorescence intensity by cubic volume of particles (see Table 3). Specific fluorescence intensities of MPS nano particles measured at excitation at 570 nm and luminescence at 590 nm were 7 times and one fourth of specific fluorescence intensities of quantum dot measured at excitation at 350 nm and luminescence at 605 nm, respectively.
  • TEOS NP containing fluorescence dye was prepared using the same method and compared with Q dot 525. Specific intensity of TEOS NP containing fluorescence dye is one third of the quantum dot thereof under the same conditions, and 1/48 of specific fluorescence intensity of quantum dot under the optimum conditions. In the case of silica nano particles containing rhodamine red, relative intensity with regard to quantum dot was improved as compared with nano silica particles containing fluorescence dye. These results suggest that improvement of the fluorescence intensity is possible by selecting appropriate dyes to be incorporated in the silica network.
  • fluorescent MPS NP can be prepared as a plurality of nano silica particles containing fluorescence regulated nano silica particles and two types of fluorescence dyes.
  • Fluorescent nano particles containing MPS NP and TEOS NP have high fluorescence intensity, and fluorescence intensity of nano silica particles can be increased as compared with fluorescence intensity of quantum dot by improving synthesis method and selection method of fluorescence dyes.
  • MPS NP has another advantage in addition to that of conventional TEOS NP.
  • MPS NP the surface layer of MPS NP can be altered with ease.
  • This reactivity of MPS NP is a consequence of existence of thiol residue on its surface layer and this existence allows, for example, alteration thereof by the use of maleimide conjugated fluorescence dye.
  • MPS NP was characterized by reaction with dye conjugated with maleimide and using fluorescent microscope and flow cytometry, and comparison was made with those of TEOS NP.
  • MPS NP was reacted with rhodamine red conjugated with maleimide, and then, particles obtained emitted fluorescence. After the reaction, washing and centrifugation were performed, and then, pellets of MPS NP changed from white to red color.
  • MPS NP revealed bright and definite fluorescent emission under the fluorescent microscope ( FIG.
  • MPS NP (average diameter about 450 nm; particle diameter distributes from 200 to 600 nm) was reacted with fluorescein-maleimide conjugate at various concentration and analyzed by flow cytometry.
  • the MPS NP emitted fluorescence at various intensities ( FIG. 11 ). According to these results, it is shown by analysis using flow cytometry that efficiency of binding of fluorescence dye on MPS NP via thiol residue is good, while the fluorescence intensity is adjustable.
  • the present inventors showed that, after surface layer alteration by the fluorescence dye, MPS NP could be utilized for flow cytometry analysis and microscopic observation.
  • TEOS NP in which rhodamine red is incorporated into particles
  • TEOS NP and MPS NP with rhodamine bound onto surface layer thereof.
  • Curves representing normalized fluorescence intensity of single particle of TEOS NP and MPS NP having rhodamine in particles thereof show favorable photostability, both still hold about more than 50% of the initial value at 250 seconds after continuous luminescence, and stabilities of the both were nearly identical ( FIG. 12 ).
  • Photostability of MPS NP having rhodamine on the surface layer was about 40% at 250 seconds thereafter.
  • the initial values, i.e., values at elapsed time zero, of TEOS NP containing rhodamine red, MPS NP containing rhodamine red, and MPS NP having rhodamine red on the surface layer were 175.889 a.u., 120.582 a.u., and 403.338 a.u., respectively, and the same at 250 seconds later was 111.351 a.u., 66.549 a.u., and 147.294 a.u., respectively. Their fluorescence could be confirmed with the naked eye. Fluorescence intensity of MPS NP with altered surface layer was the highest among all NP tested, while photostability was not necessarily better than others.
  • Table 4 (Zeta potential of nano silica particle) (Nano particle) (Zeta potential) TEOS NP -38.7 TEOS NP containing rhodamine red -36.0 MPS NP -52.2 MPS NP containing rhodamine red -52.1 MPS NP presenting rhodamine red surface layer -32.2 MPS NP presenting NeutrAvidin surface layer -19.2
  • zeta potential of MPS NP is far more negative than zeta potential of TEOS NP. It is considered that a difference of zeta potential is caused due to that OH-group is present on the surface for TEOS particle and SH-group is present on the surface in addition to OH-group for MPS particle.
  • SH-group is present on the surface in addition to OH-group for MPS particle.
  • SA it is understood that in MPS particles, many SH-groups are present on the surface as compared with TEOS particle.
  • Zeta potentials of MPS NP and TEOS NP containing rhodamine red therein were not significantly different from zeta potential for the case without dye, respectively.
  • the present inventors investigated surface layer alteration characteristics by use of flow cytometry, fluorescence image analysis, and fluorescent microscope.
  • the present inventors performed dot blotting by using these NP for comparison of simplicity between MPS NP surface layer and TEOS NP surface layer.
  • Each of equal amounts of NP was dropped onto a glass slide and dried, then reacted with the solution containing Cy3 conjugated anti-goat IgG and investigated with fluorescence image analyzer.
  • MPS NP spot showed that intensity resulting from Cy3 conjugated anti-goat IgG is markedly higher than the spot of TEOS NP ( FIG. 13a ).
  • Fluorescence intensity of the MPS was about 3-folds of that of TEOS NP ( FIG. 13b ).
  • the NP solution was mixed with protein solution containing either green fluorescent protein (GFP) or phycoerythrin conjugated streptavidin. After mixed with GFP or phycoerythrin conjugated streptavidin, flow cytometry peak relating to MPS NP shifted remarkably to the right due to fluorescence from GFP as compared with TEOS NP ( FIG. 14 ).
  • GFP green fluorescent protein
  • phycoerythrin conjugated streptavidin After mixed with GFP or phycoerythrin conjugated streptavidin, flow cytometry peak relating to MPS NP shifted remarkably to the right due to fluorescence from GFP as compared with TEOS NP ( FIG. 14 ).
  • TEOS by silylation treatment of nano silica particles with 3-mercaptopropyl-trimethoxysilane or N1-[3-(trimethoxysilyl-propyl)diethylene triamine was already reported.
  • the silylation treated silane NP was conjugated with oligonucleotide being disulfide altered via thiol/disulfide exchange reaction and conjugated with enzyme and antibody by cross-linking with amine by use of glutaraldehyde.
  • nano silica particles were prepared and surface layer was altered via cohydrolysis by using TEOS and various organic silane reagents. This method could reduce agglomeration of amino-altered NP.
  • MPS NP was synthesized via one-stage synthesis (one-pod synthesis) and thiol residue was synthesized on the surface layer thereof without other additional procedures.
  • This MPS NP showed extremely good dispersion as compared with TEOS NP and larger absolute value of zeta potential in negative value.
  • MPS NP gives assurance for various biological applications for possibility relating to surface layer alteration, and its aspects including bioassay and drug delivery system are worthwhile for further investigations in regard to availability thereof.
  • Thiol residue on NP has various advantages for alteration and functionalization of nano particles. Thiol residue can be reacted with various chemical coupling agents (e.g., alkyl halide and maleimide). The thiol group can easily form covalent binding with other molecule.
  • MPS silica particles of the present invention primary reaction detection in which the particle is directly reacted with fluorescently-labeled protein to be bound on the particle and is assessed by flow cytometry, and secondary reaction detection in which antigen solution is reacted to be bound on the particle, washed, and reacted with fluorescently-labeled antibody, were performed.
  • FITC labeled anti-sheep antibody IgG solutions at various concentrations (39.1 to 10,000 ng/ml) were prepared. 5 ⁇ l of FITC labeled anti-sheep antibody IgG solution with each concentration and 5 ⁇ l of particle solution were added to a test tube for flow cytometry, mixed well, diluted with 490 ⁇ l of distilled water (without allowing time especially for reaction), and measured by the flow cytometry.
  • FIG. 16 shows that FITC labeled anti-sheep antibody IgG solution binds to particles in concentration dependent fashion in short time
  • upper graph shows correlation between concentration of FITC labeled anti-sheep antibody IgG solution and fluorescence intensity detected by binding thereof, while vertical axis represents fluorescence intensity and horizontal axis represents concentration of FITC labeled anti-sheep antibody IgG solution.
  • Lower graph is a chart which shows that each peak varies in concentration dependent fashion by antibody concentration. Measurements could be made quickly from 70 ng/ml to 7 ⁇ g/ml for a sample as trace amount as 5 ⁇ l. (Graph at upper part in FIG.
  • FITC labeled anti-sheep antibody IgG solutions at various concentrations (0.01 to 100 ng/ml) were prepared. 600 ⁇ l of FITC labeled anti-sheep antibody IgG solutions at various concentrations and 5 ⁇ l of particle solution were added to the test tube for flow cytometry, mixed well, reacted for 10 minutes, and then measured by the flow cytometry.
  • FIG. 17 shows that FITC labeled anti-sheep antibody IgG solution binds to particles in concentration dependent fashion and that, in particular, detection of binding thereof is possible even at concentration less than ng/ml
  • upper graph shows correlation between FITC labeled anti-sheep antibody IgG solution concentration and fluorescence intensity detected from particles by binding thereof
  • vertical axis represents fluorescence intensity
  • horizontal axis represents FITC labeled anti-sheep antibody IgG solution concentration.
  • Lower graph is a chart which shows that each peak varies in concentration dependent fashion by antibody concentration. (Graph at upper part in FIG.
  • FIG. 18 shows that FITC labeled anti-sheep antibody IgG solution binds in short time to particles of sheep anti-glutathione-S-transferase antibody solution, being antigen, in concentration dependent fashion
  • upper graph shows correlation between concentration of sheep anti-glutathione- S-transferase antibody solution and fluorescence intensity detected from particles by binding thereof
  • vertical axis represents fluorescence intensity
  • horizontal axis represents sheep anti-glutathione-S-transferase antibody solution concentration.
  • lower graph is a chart and shows that each peak varies in antibody concentration dependent fashion. Experimental results show that multiple-stage binding reaction occurs in amount dependent fashion on the particles, thereby resulting in the detection. (Graph at upper part in FIG.
  • Quantitative determination by flow cytometry has not been generalized yet even for particles with pore.
  • One reason for that is difficulty of controls of effective adherence surface area.
  • no report is available till today which reports good repeatability of signals suited for quantitative determination relating to scattered light (FSC, SCC) required for quantitative determination in the flow cytometry. Therefore, identification of a group of particles with fluorescence variation is difficult as long as conventional art is involved, and hence, it is considered that drawbacks of difficulty of accurate quantitative determination are not removed.
  • a group of particles is first identified by scattered light in the flow cytometry and then changes in the fluorescence of the group of particles are measured.
  • Size distribution of particles was assessed using flow cytometry. Comparison was performed also with commercial standard beads - Fluoresbrite from Polyscience Corp.. Side scatter (SSC) was used for parameters for flow cytometry. Procedures, conditions and protocol for comparative experiments are as shown below. Thiol silica particles of the present invention (MPS, MPES, MPDMS) were synthesized as described in Example 2 or Example 5. Dilution of particles was performed, and measurement and assessment were performed by flow cytometry FACS CaliburHG.
  • FIG. 19 green; YG1, pink: YG-0.75, light blue; YG-0.5, orange; YG-0.2, FIG. 20 ; green; 33-2894-6, pink: 33-2899-1, light blue; 33-2899-2, orange; 33-2909-3)
  • middle area shows electron microscopic images of each particle.
  • FIG. 19 upper left; YG1, upper right: YG-0.75, lower left; YG-0.5, lower right; YG-0.2, FIG. 20 ; upper left; 33-2894-6, upper right; 33-2899-1, lower left; 33-2899-2, lower right; 33-2909-3) It is understood from these microscopic images that size of each particle is controlled favorably.
  • Silica particles used here were synthesized according to descriptions of Examples 2 to 5, 13 to 17.
  • results shown in (Embodiment of application to beads assay) and (Comparison with commercial standard beads) include some deviations between assessment by flow cytometry and assessment by electron microscope, favorable size control was confirmed with both commercial standard beads and beads of the present invention. Finding from assessment by flow cytometry showed that beads of the present invention are virtually favorable as compared with commercial standard beads.
  • pore distribution and specific surface area of nano silica particles of the present invention were measured.
  • specific surface area pore distribution measuring device SA-3100 from Beckman-Coulter Corp. was used as measuring instrument.
  • Pore volume was 0.0159 (m 3 /g). Pore volume is small as the number of pores is low. Pore volume of nano silica particles of the present invention is at least less than 0.1 (m 3 /g) even though various possibilities are taken into considerations.
  • pore volume influences of particle size are little, and characterization to be particles with small number of pores may be possible.
  • Silica particles to be used were synthesized according to the description of Example 6. Nano silica particles containing rhodamine were given intraperitoneally to mouse (Balbc/6J, 9-weeks old, male). Cells in the peritoneal cavity were collected next day. Observation of cells obtained by the fluorescence microscope revealed cells with which fluorescence of rhodamine was admitted as shown in the figure. Additional observation of intraperitoneal cells by the electron microscope revealed nano silica particles in cell cytoplasm as shown in the figure. These observations indicate that cells could be labeled using fluorescence nano silica particle as the probe by use of phagocytic capacity of macrophage. Further, labeled cells can be detected as fluorescence by fluorescence microscope and as particle images by electron microscope.
  • the present invention can be provided and utilized as a labeling substance or a marker for qualitative test and quantitative test for such as prophylactic agent, therapeutic agent, diagnostic agent, diagnostic and therapeutic agent or the like in dental, medical and veterinary fields regardless of fields.
  • nano particles of the present invention can be utilized in application fields of industrial materials as well as pharmaceutical and cosmetic materials such as nano structure reforming material, optical function coating material, fluorescent material, electronic parts material, magnetic recording material, and polishing material.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Polymers & Plastics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Materials Engineering (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Composite Materials (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Silicon Compounds (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Silicon Polymers (AREA)

Claims (7)

  1. Siliciumdioxidverbindungsteilchen, das aus einer oder mehreren Silanverbindungen ausgewählt aus der Gruppe bestehend aus Mercaptopropyltrimethoxysilan (MPS), Mercaptopropyltriethoxysilan (MPDMS), Mercaptopropylmethyldimethoxysilan (MPDMS), Trimethoxy-[2-(7-oxabicyclo[4.1.0]-hepto-3-yl)-ethyl]-silan (EpoPS), Thiocyanatopropyltriethoxysilan (TCPS) und Acryloxypropyltrimethoxysilan (AcPS) gebildet ist, wobei das Siliciumdioxidverbindungsteilchen durch ein Herstellungsverfahren hergestellt worden ist, wobei das Herstellungsverfahren umfasst.
    (a) einen Schritt zur Herstellung einer Mischung von Silanverbindung und Ammoniakwasser, und
    (b) einen Schritt zur Umsetzung der Silanverbindung und des Ammoniakwassers, wobei das Verfahren so durchgeführt wird, dass Ammoniakwasser und Temperaturbedingung in den Schritten (a) und (b) beide die folgenden Bedingungen erfüllen:
    (i) hohe Temperatur im Bereich von 80 bis 100°C,
    (ii) eine Konzentration von Ammoniakwasser nicht weniger als 25 Gew.-%.
  2. Standardmarker, der das Siliciumdioxidverbindungsteilchen gemäß Anspruch 1 umfasst, verwendet für Fließzytometrie, Größenmarker, Kugelessay und Sonde.
  3. Träger, der das Siliciumdioxidverbindungsteilchen gemäß Anspruch 1 enthält, verwendet zur Synthese von Nukleinsäure oder Protein oder Zellkulturanwendung.
  4. Herstellungsverfahren eines Siliciumdioxidverbindungsteilchens, das umfasst:
    (a) einen Schritt zur Herstellung einer Mischung von Silanverbindung und Ammoniakwasser, und
    (b) einen Schritt zur Umsetzung der Silanverbindung und des Ammoniakwassers,
    wobei die Silanverbindung eine Silanverbindung oder mehrere Silanverbindungen ausgewählt aus der Gruppe bestehend aus Mercaptopropyltrimethoxysilan (MPS), Mercaptopropyltriethoxysilan (MPES), Mercaptopropylmethyldimethoxysilan (MPDMS), Trimethoxy[2-(7-oxabicyclo[4.1.0]-hepto-3-yl)-ethyl]-silan (EpoPS), Thiocyanatopropyltriethoxysilan (TCPS) und Acrylpropyltrimethoxysilan (AcPS) ist und das Verfahren so durchgeführt wird, dass Ammoniakwasser und Temperaturbedingung in den Schritten (a) und (b) beide der folgenden Bedingungen erfüllen:
    (i) hohe Temperatur im Bereich von 80 bis 100°C und
    (ii) eine Konzentration von Ammoniakwasser nicht weniger als 25 Gew.-%.
  5. Verfahren nach Anspruch 4, bei dem Schritt (b) in Gegenwart von Isopropanol durchgeführt wird.
  6. Siliciumdioxidverbindungsteilchen nach Anspruch 1, das ein funktionelles Material auf der Oberflächenschicht oder darin enthält, wobei das funktionelle Material ausgewählt ist aus einer Gruppe bestehend aus fluoreszierendem Material, Protein, Nukleotid, Oligonukleotid, Zuckerkette und Kombinationen derselben.
  7. Siliciumdioxidverbindungsteilchen nach Anspruch 6, bei dem, wenn das funktionelle Material ein fluoreszierendes Material ist, das fluoreszierende Material ausgewählt ist aus einer Gruppe bestehend aus Rhodamin rot, Fluoreszein, Hexansäure-6-(tetramethylrhodamin-5-carboxamid), Hexansäure-5-(tetramethylrhodamin-5-carboxamid), und Trisdichlorruthenium (II)hexahydrat und das fluoreszierende Material im Inneren enthalten ist oder auf der Oberflächenschicht vorliegt, unabhängig oder in einer Form gebunden an eine Verbindung ausgewählt aus N-Hydroxysuccinimid (NHS), Isothiocyanat (ITC) und Maleimid.
EP07744912.2A 2006-06-08 2007-06-07 Verfahren zur herstellung von neuem siliciumdioxid-nanoteilchen und verwendung des siliciumdioxid-nanoteilchens Not-in-force EP2031010B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006160107 2006-06-08
PCT/JP2007/061587 WO2007142316A1 (ja) 2006-06-08 2007-06-07 新規なナノシリカ粒子の製造方法と用途

Publications (3)

Publication Number Publication Date
EP2031010A1 EP2031010A1 (de) 2009-03-04
EP2031010A4 EP2031010A4 (de) 2012-04-04
EP2031010B1 true EP2031010B1 (de) 2014-04-23

Family

ID=38801562

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07744912.2A Not-in-force EP2031010B1 (de) 2006-06-08 2007-06-07 Verfahren zur herstellung von neuem siliciumdioxid-nanoteilchen und verwendung des siliciumdioxid-nanoteilchens

Country Status (4)

Country Link
US (1) US8455255B2 (de)
EP (1) EP2031010B1 (de)
JP (1) JP5311340B2 (de)
WO (1) WO2007142316A1 (de)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9738562B2 (en) 2013-06-25 2017-08-22 Carboncure Technologies Inc. Methods and compositions for concrete production
US9758437B2 (en) 2013-06-25 2017-09-12 Carboncure Technologies Inc. Apparatus for delivery of carbon dioxide to a concrete mix in a mixer and determining flow rate
US9790131B2 (en) 2013-02-04 2017-10-17 Carboncure Technologies Inc. System and method of applying carbon dioxide during the production of concrete
US10246379B2 (en) 2013-06-25 2019-04-02 Carboncure Technologies Inc. Methods and compositions for concrete production
US10570064B2 (en) 2014-04-07 2020-02-25 Carboncure Technologies Inc. Integrated carbon dioxide capture
US10654191B2 (en) 2012-10-25 2020-05-19 Carboncure Technologies Inc. Carbon dioxide treatment of concrete upstream from product mold
US10927042B2 (en) 2013-06-25 2021-02-23 Carboncure Technologies, Inc. Methods and compositions for concrete production
US11660779B2 (en) 2016-04-11 2023-05-30 Carboncure Technologies Inc. Methods and compositions for treatment of concrete wash water
US11958212B2 (en) 2017-06-20 2024-04-16 Carboncure Technologies Inc. Methods and compositions for treatment of concrete wash water

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007142316A1 (ja) * 2006-06-08 2007-12-13 The University Of Tokushima 新規なナノシリカ粒子の製造方法と用途
JP5709292B2 (ja) * 2007-12-06 2015-04-30 国立大学法人徳島大学 ナノ機能性シリカ粒子およびその製造方法
JP2012532211A (ja) * 2009-06-30 2012-12-13 スリーエム イノベイティブ プロパティズ カンパニー ナノ粒子を用いる蛍光が改善された透明蛍光構造体、その製造方法、及び使用
JP5671836B2 (ja) * 2010-04-27 2015-02-18 コニカミノルタ株式会社 有機蛍光色素内包シリカナノ粒子、その製造方法、及びそれを用いた生体物質標識剤
US8584864B2 (en) 2010-11-19 2013-11-19 Coldcrete, Inc. Eliminating screens using a perforated wet belt and system and method for cement cooling
WO2012118829A2 (en) * 2011-02-28 2012-09-07 Novan, Inc. Tertiary s-nitrosothiol-modified nitricoxide-releasing xerogels and methods of using the same
US8642214B2 (en) 2011-08-25 2014-02-04 Uchicago Argonne, Llc Silicon-carbonaceous encapsulated materials
WO2015123769A1 (en) 2014-02-18 2015-08-27 Carboncure Technologies, Inc. Carbonation of cement mixes
JP6709734B2 (ja) * 2014-10-31 2020-06-17 信一郎 礒部 アルコキシシリル基含有有機ｅｌ色素およびその製造方法
EP3280334A4 (de) * 2015-04-06 2019-01-16 University of Miami Vorrichtung und verfahren für den nachweis einer krankheit
JP7086894B2 (ja) * 2019-06-05 2022-06-20 信越化学工業株式会社 オルガノポリシロキサンおよびそれを含む活性エネルギー線硬化性組成物
CN112300778B (zh) * 2019-07-30 2023-11-03 国家纳米科学中心 一种圆偏振发光物质及其制备方法和应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3642445A (en) * 1970-04-30 1972-02-15 Us Interior Utilization of coal-burning power plant by-products
US4246209A (en) * 1979-03-02 1981-01-20 Ramu International Freezing inorganic particulate slurries
US4428895A (en) * 1979-03-02 1984-01-31 Blasch Precision Ceramics, Inc. Composite inorganic structures and process of producing same
US4683334A (en) * 1985-04-30 1987-07-28 E. I. Du Pont De Nemours & Company Modified 8-ring zeolites as catalysts for conversion of methanol and ammonia to dimethylamine
DE3616133A1 (de) * 1985-09-25 1987-11-19 Merck Patent Gmbh Kugelfoermige sio(pfeil abwaerts)2(pfeil abwaerts)-partikel
US4927749A (en) * 1986-04-09 1990-05-22 Jeanette Simpson Reagent for cell separation
AU626348B2 (en) * 1988-10-14 1992-07-30 Mallinckrodt, Inc. Radiolabelled particulate composition
JPH0633337B2 (ja) * 1989-04-18 1994-05-02 信越化学工業株式会社 球状ポリオルガノシルセスキオキサン微粒子及びその製造方法
JPH0623254B2 (ja) * 1990-03-19 1994-03-30 信越化学工業株式会社 アクリロキシ基、メルカプト基含有シルセスキオキサン球状微粉末の製造方法
JPH0617476B2 (ja) * 1990-09-04 1994-03-09 工業技術院長 有機基修飾シリカ粒子、その製造方法および該粒子をフィラーとする樹脂組成物
JPH04202325A (ja) 1990-11-29 1992-07-23 Toray Ind Inc 球状シリコーン微粒子
DK0529175T3 (da) * 1991-07-22 1995-11-06 Bracco Int Bv Konjugater chelaret med paramagnetiske metaller til målsøgning
EP0759950B1 (de) * 1994-05-19 2000-05-24 Minnesota Mining And Manufacturing Company Polymergegenstand mit verbesserter hydrophiler eigenschaft und verfahren zu seiner herstellung
US6160067A (en) * 1995-10-03 2000-12-12 Dsm N.V. Reactive silica particles, process for manufacturing the same, use of the same
JPH10264521A (ja) * 1997-03-26 1998-10-06 Mitsubishi Paper Mills Ltd 可逆性感熱記録材料
AUPP004497A0 (en) * 1997-10-28 1997-11-20 University Of Melbourne, The Stabilized particles
JP2000239388A (ja) * 1999-02-24 2000-09-05 Pola Chem Ind Inc メルカプト基を有する珪酸化合物
US6417246B1 (en) * 1999-09-21 2002-07-09 Jenerica/Pentron Incorporated Dental composite materials
JP2003513122A (ja) * 1999-10-28 2003-04-08 スリーエム イノベイティブ プロパティズ カンパニー 組成物およびそれらから製造された物品
US7195780B2 (en) * 2002-10-21 2007-03-27 University Of Florida Nanoparticle delivery system
JP4132648B2 (ja) * 2000-12-04 2008-08-13 ポーラ化成工業株式会社 有機修飾シリカコーティング粉体及びその構成要因である有機修飾シリカ
US6787629B2 (en) * 2001-11-02 2004-09-07 Pentron Clinical Technologies, Llc Dental resin materials, method of manufacture, and uses thereof
WO2003003015A2 (en) * 2001-06-28 2003-01-09 Advanced Research And Technology Institute, Inc. Methods of preparing multicolor quantum dot tagged beads and conjugates thereof
CA2491110A1 (en) 2001-06-29 2003-01-09 Nanomics Biosystems Pty, Ltd. Synthesis and use of organosilica particles
DE60232942D1 (de) * 2001-10-09 2009-08-27 Mitsubishi Chem Corp Strahlungshärtbare Beschichtungszusammensetzung
US6719535B2 (en) * 2002-01-31 2004-04-13 Eksigent Technologies, Llc Variable potential electrokinetic device
EP2045439B1 (de) * 2002-05-24 2010-07-21 3M Innovative Properties Company Verwendung von oberflächenmodifizierten Nanopartikeln zur Ölgewinnung
AU2002950953A0 (en) * 2002-08-23 2002-09-12 Genera Biosystems Pty Ltd Coded nucleic acid carriers
US20060018966A1 (en) * 2003-07-22 2006-01-26 Lin Victor S Antimicrobial mesoporous silica nanoparticles
DE10355409A1 (de) * 2003-11-25 2005-06-30 Magnamedics Gmbh Sphärische, magnetische Silicagel-Träger mit vergrößerter Oberfläche für die Aufreinigung von Nukleinsäuren
DE102004011110A1 (de) * 2004-03-08 2005-09-22 Merck Patent Gmbh Verfahren zur Herstellung monodisperser SiO2-Partikel
EP1635359A3 (de) * 2004-09-09 2007-01-17 Konica Minolta Medical & Graphic, Inc. Strahlungsbildwandler
WO2006070582A1 (ja) 2004-12-09 2006-07-06 Techno Network Shikoku. Co., Ltd. 標識分子含有シリカ球の調製方法
JP4154388B2 (ja) 2004-12-27 2008-09-24 キヤノン株式会社 被対象物を透過した電磁波の状態を検出するための検出装置
WO2007074722A1 (ja) * 2005-12-27 2007-07-05 The Furukawa Electric Co., Ltd. 蛍光ナノシリカ粒子、ナノ蛍光材料、それを用いたバイオチップ及びそのアッセイ法
WO2007142316A1 (ja) * 2006-06-08 2007-12-13 The University Of Tokushima 新規なナノシリカ粒子の製造方法と用途
JP5089589B2 (ja) * 2006-08-10 2012-12-05 古河電気工業株式会社 吸光物質含有コロイドシリカ粒子、ナノ吸光材料、及び吸光標識ナノビーズキット
JP5709292B2 (ja) * 2007-12-06 2015-04-30 国立大学法人徳島大学 ナノ機能性シリカ粒子およびその製造方法

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10654191B2 (en) 2012-10-25 2020-05-19 Carboncure Technologies Inc. Carbon dioxide treatment of concrete upstream from product mold
US10683237B2 (en) 2013-02-04 2020-06-16 Carboncure Technologies Inc. System and method of applying carbon dioxide during the production of concrete
US9790131B2 (en) 2013-02-04 2017-10-17 Carboncure Technologies Inc. System and method of applying carbon dioxide during the production of concrete
US10246379B2 (en) 2013-06-25 2019-04-02 Carboncure Technologies Inc. Methods and compositions for concrete production
US9738562B2 (en) 2013-06-25 2017-08-22 Carboncure Technologies Inc. Methods and compositions for concrete production
US9758437B2 (en) 2013-06-25 2017-09-12 Carboncure Technologies Inc. Apparatus for delivery of carbon dioxide to a concrete mix in a mixer and determining flow rate
US10927042B2 (en) 2013-06-25 2021-02-23 Carboncure Technologies, Inc. Methods and compositions for concrete production
US11773031B2 (en) 2013-06-25 2023-10-03 Carboncure Technologies Inc. Apparatus for delivery of a predetermined amount of solid and gaseous carbon dioxide
US11773019B2 (en) 2013-06-25 2023-10-03 Carboncure Technologies Inc. Methods and compositions for concrete production
US10570064B2 (en) 2014-04-07 2020-02-25 Carboncure Technologies Inc. Integrated carbon dioxide capture
US11878948B2 (en) 2014-04-07 2024-01-23 Carboncure Technologies Inc. Integrated carbon dioxide capture
US11660779B2 (en) 2016-04-11 2023-05-30 Carboncure Technologies Inc. Methods and compositions for treatment of concrete wash water
US11958212B2 (en) 2017-06-20 2024-04-16 Carboncure Technologies Inc. Methods and compositions for treatment of concrete wash water

Also Published As

Publication number Publication date
JP5311340B2 (ja) 2013-10-09
EP2031010A4 (de) 2012-04-04
US20100330582A1 (en) 2010-12-30
EP2031010A1 (de) 2009-03-04
US8455255B2 (en) 2013-06-04
JPWO2007142316A1 (ja) 2009-10-29
WO2007142316A1 (ja) 2007-12-13

Similar Documents

Publication Publication Date Title
EP2031010B1 (de) Verfahren zur herstellung von neuem siliciumdioxid-nanoteilchen und verwendung des siliciumdioxid-nanoteilchens
JP5709292B2 (ja) ナノ機能性シリカ粒子およびその製造方法
JP4572274B2 (ja) 標的生体分子標識用もしくは標的細胞標識用の蛍光シリカ粒子組成物、及びこれを用いたフローサイトメトリー用マルチプレックシングキット
JP2008533214A (ja) ナノ粒子捕捉球状複合体、それらの製造プロセスおよび使用
Kim et al. Dual-mode fluorophore-doped nickel nitrilotriacetic acid-modified silica nanoparticles combine histidine-tagged protein purification with site-specific fluorophore labeling
JP5367915B2 (ja) 生体分子を結合させた機能性分子含有シリカナノ粒子の製造方法
JPWO2010016289A1 (ja) 量子ドットを含有する蛍光標識剤
JP2005528466A (ja) 種々の発光強度及び周波数を有する発光性の球状非自己蛍光性シリカゲル
JP2009274923A (ja) 粒子表面にアミノ基を有するシリカ粒子の製造方法、粒子表面にアミノ基を有するシリカ粒子、及びそれを用いた複合粒子
JP5224330B2 (ja) コア‐シェル構造のシリカナノ粒子の製造方法、コア‐シェル構造のシリカナノ粒子、及びそれを用いた標識試薬
JP5202857B2 (ja) 分散性が高く、非特異的吸着を防止した複合粒子、複合粒子コロイド、それを用いた分析試薬、及び複合粒子の製造方法
JPWO2009066548A1 (ja) 半導体ナノ粒子、それを用いた蛍光標識物質及び分子・細胞イメージング法
Alsolmy et al. A comparative study of fluorescein isothiocyanate-encapsulated silica nanoparticles prepared in seven different routes for developing fingerprints on non-porous surfaces
JP4107873B2 (ja) 発光性微粒子
JP2011225381A (ja) 表層制御積層シリカナノ粒子及びその製造方法
Dembele et al. Zwitterionic silane copolymer for ultra-stable and bright biomolecular probes based on fluorescent quantum dot nanoclusters
WO2021187492A1 (ja) ケイ酸塩系基材と希土類化合物との複合体、発光ナノ粒子、細胞の検出方法、動物の治療方法、医療装置、及びケイ酸塩系基材と希土類化合物との複合体の製造方法
CN1231760C (zh) 用于生物材料标记的稀土纳米粒子、其制备方法及用途
KR20170097520A (ko) 실란-란탄계 착물 복합체 및 가교반응을 이용한 형광 실리카 나노입자 및 이의 제조방법
KR101368076B1 (ko) 수용액에서 우수한 분산성을 가지는 표면 개질된 형광 실리카 나노입자 및 그 제조방법
JP5168092B2 (ja) 半導体ナノ粒子標識剤
US8735084B2 (en) Biochip array with a three-dimensional structure and method for forming the same
WO2009144983A1 (ja) 無機ナノ粒子標識剤
Yang et al. SiO2 particles with CdTe nanocrystals: surface modification and bioconjugation for labeling applications
JP2022187940A (ja) 粒子およびその製造方法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20081218

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

DAX Request for extension of the european patent (deleted)
RBV Designated contracting states (corrected)

Designated state(s): CH DE FR GB LI

A4 Supplementary search report drawn up and despatched

Effective date: 20120306

RIC1 Information provided on ipc code assigned before grant

Ipc: C08G 77/02 20060101ALI20120229BHEP

Ipc: G01N 33/48 20060101ALI20120229BHEP

Ipc: C08G 77/28 20060101ALI20120229BHEP

Ipc: G01N 15/00 20060101ALI20120229BHEP

Ipc: C09K 11/06 20060101ALI20120229BHEP

Ipc: C08G 77/06 20060101AFI20120229BHEP

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 15/00 20060101ALI20120501BHEP

Ipc: C08G 77/02 20060101ALI20120501BHEP

Ipc: G01N 33/48 20060101ALI20120501BHEP

Ipc: C08G 77/28 20060101ALI20120501BHEP

Ipc: C08G 77/06 20060101AFI20120501BHEP

Ipc: C09K 11/06 20060101ALI20120501BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20131121

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): CH DE FR GB LI

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: NOVAGRAAF INTERNATIONAL SA, CH

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602007036246

Country of ref document: DE

Effective date: 20140605

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602007036246

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20150126

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602007036246

Country of ref document: DE

Effective date: 20150126

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20150603

Year of fee payment: 9

Ref country code: CH

Payment date: 20150612

Year of fee payment: 9

Ref country code: DE

Payment date: 20150602

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20150608

Year of fee payment: 9

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602007036246

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20160607

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20170228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160630

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160630

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160630

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170103

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160607